IBDEI2TK ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,44967,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44967,1,3,0)
 ;;=3^Merkel Cell CA,Left Upper Eyelid,Incl Canthus
 ;;^UTILITY(U,$J,358.3,44967,1,4,0)
 ;;=4^C4A.121
 ;;^UTILITY(U,$J,358.3,44967,2)
 ;;=^5157276
 ;;^UTILITY(U,$J,358.3,44968,0)
 ;;=C4A.111^^170^2241^73
 ;;^UTILITY(U,$J,358.3,44968,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44968,1,3,0)
 ;;=3^Merkel Cell CA,Right Upper Eyelid,Incl Canthus
 ;;^UTILITY(U,$J,358.3,44968,1,4,0)
 ;;=4^C4A.111
 ;;^UTILITY(U,$J,358.3,44968,2)
 ;;=^5157274
 ;;^UTILITY(U,$J,358.3,44969,0)
 ;;=C4A.112^^170^2241^72
 ;;^UTILITY(U,$J,358.3,44969,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44969,1,3,0)
 ;;=3^Merkel Cell CA,Right Lower Eyelid,Incl Canthus
 ;;^UTILITY(U,$J,358.3,44969,1,4,0)
 ;;=4^C4A.112
 ;;^UTILITY(U,$J,358.3,44969,2)
 ;;=^5157275
 ;;^UTILITY(U,$J,358.3,44970,0)
 ;;=I78.1^^170^2242^9
 ;;^UTILITY(U,$J,358.3,44970,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44970,1,3,0)
 ;;=3^Nevus,Non-Neoplastic
 ;;^UTILITY(U,$J,358.3,44970,1,4,0)
 ;;=4^I78.1
 ;;^UTILITY(U,$J,358.3,44970,2)
 ;;=^269807
 ;;^UTILITY(U,$J,358.3,44971,0)
 ;;=L60.3^^170^2242^2
 ;;^UTILITY(U,$J,358.3,44971,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44971,1,3,0)
 ;;=3^Nail Dystrophy
 ;;^UTILITY(U,$J,358.3,44971,1,4,0)
 ;;=4^L60.3
 ;;^UTILITY(U,$J,358.3,44971,2)
 ;;=^5009236
 ;;^UTILITY(U,$J,358.3,44972,0)
 ;;=L92.1^^170^2242^4
 ;;^UTILITY(U,$J,358.3,44972,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44972,1,3,0)
 ;;=3^Necrobiosis Lipoidica NEC
 ;;^UTILITY(U,$J,358.3,44972,1,4,0)
 ;;=4^L92.1
 ;;^UTILITY(U,$J,358.3,44972,2)
 ;;=^5009462
 ;;^UTILITY(U,$J,358.3,44973,0)
 ;;=L20.81^^170^2242^8
 ;;^UTILITY(U,$J,358.3,44973,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44973,1,3,0)
 ;;=3^Neurodermatitis,Atopic
 ;;^UTILITY(U,$J,358.3,44973,1,4,0)
 ;;=4^L20.81
 ;;^UTILITY(U,$J,358.3,44973,2)
 ;;=^5009108
 ;;^UTILITY(U,$J,358.3,44974,0)
 ;;=D48.5^^170^2242^7
 ;;^UTILITY(U,$J,358.3,44974,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44974,1,3,0)
 ;;=3^Neoplasm,Skin,Uncertain Behavior
 ;;^UTILITY(U,$J,358.3,44974,1,4,0)
 ;;=4^D48.5
 ;;^UTILITY(U,$J,358.3,44974,2)
 ;;=^267777
 ;;^UTILITY(U,$J,358.3,44975,0)
 ;;=D49.2^^170^2242^6
 ;;^UTILITY(U,$J,358.3,44975,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44975,1,3,0)
 ;;=3^Neoplasm,Bone/Soft Tissue/Skin,Unspec Behavior
 ;;^UTILITY(U,$J,358.3,44975,1,4,0)
 ;;=4^D49.2
 ;;^UTILITY(U,$J,358.3,44975,2)
 ;;=^5002272
 ;;^UTILITY(U,$J,358.3,44976,0)
 ;;=L60.0^^170^2242^3
 ;;^UTILITY(U,$J,358.3,44976,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44976,1,3,0)
 ;;=3^Nail,Ingrowing
 ;;^UTILITY(U,$J,358.3,44976,1,4,0)
 ;;=4^L60.0
 ;;^UTILITY(U,$J,358.3,44976,2)
 ;;=^5009234
 ;;^UTILITY(U,$J,358.3,44977,0)
 ;;=L60.9^^170^2242^1
 ;;^UTILITY(U,$J,358.3,44977,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44977,1,3,0)
 ;;=3^Nail Disorder,Unspec
 ;;^UTILITY(U,$J,358.3,44977,1,4,0)
 ;;=4^L60.9
 ;;^UTILITY(U,$J,358.3,44977,2)
 ;;=^5009240
 ;;^UTILITY(U,$J,358.3,44978,0)
 ;;=Z91.19^^170^2242^10
 ;;^UTILITY(U,$J,358.3,44978,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44978,1,3,0)
 ;;=3^Noncompliance w/ Medical Treatment/Regimen
 ;;^UTILITY(U,$J,358.3,44978,1,4,0)
 ;;=4^Z91.19
 ;;^UTILITY(U,$J,358.3,44978,2)
 ;;=^5063618
 ;;^UTILITY(U,$J,358.3,44979,0)
 ;;=Z23.^^170^2242^5
 ;;^UTILITY(U,$J,358.3,44979,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44979,1,3,0)
 ;;=3^Need for Immunization(s)
